hasi

We review the current understanding on the IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.

The emerging role of the IL-17B/IL-17RB pathway in cancer, published in  Frontiers in Immunology and co-authoring Jeremy Bastid, Cécile Dejou, Aurélie Docquier and Nathalie Bonnefoy (OREGA Biotech).

The review article is accessible here.